Business
Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Stifel 2025 Virtual Immunology and Inflammation Forum. Fireside Chat: Monday, September 15, 2025 at 4:00-4:25 pm ET in Track 1Location: Virtual A live webcast and archived replay of the fireside chat will be available on the Com
About this update from Vor Biopharma Inc.
CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Stifel 2025 Virtual Immunology and Inflammation Forum. Fireside Chat: Monday, September 15, 2025 at 4:00-4:25 pm ET in Track 1 Location: Virtual A live webcast and archived replay of the fireside chat will be available on the Company’s website at: https://ir.vorbio.com/events-presentations/ About Vor Bio Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com . Media & Investor Contacts: Carl Mauch [email protected] Sarah Spencer [email protected]
View stock analysis, news, and events for Vor Biopharma Inc.